The FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus genotype 3 infections. The FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Evidence of fibrosis was common in older patients with ...
(PRINCETON, N.J., OCTOBER 15, 2015) – Bristol-Myers Squibb (NYSE:BMY) today announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in ...
It has been suggested that a sustained virologic response (SVR) can be achieved in patients infected with hepatitis C virus (HCV) of genotype 2 or 3 with a shorter duration of pegylated interferon ...
The researchers found that the rate of sustained virologic response at 12 weeks was 99.1% among genotype 1-infected patients in the eight-week group and 99.7% in the 12-week group. HealthDay News — ...
Daklinza in combination with sofosbuvir is the first 12-week, all-oral therapy that offers SVR12 for the vast majority of genotype 3 patients Announcement marks the first approval of Daklinza in the ...
The VOYAGE-1 and VOYAGE-2 trials included HCV genotype 1, 2, 3, 4, or 6 infected patients with cirrhosis (VOYAGE-1) or compensated cirrhosis (VOYAGE-2) who were ...
All-Oral Combination of Investigational Hepatitis C (HCV) Compounds Daclatasvir and GS-7977 Achieved Sustained Virologic Response (SVR4) in 100% of Genotype 1 and 91% of Genotype 2 and 3 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. BARCELONA — In this exclusive video interview at ...
Patients recruited to the study were mostly male, Caucasian and in their fourth decade of life ( Table 1), consistent with the epidemiology of HIV infected patients in Australia. HCV genotype was ...
This approval marks the first time patients with chronic hepatitis C virus (HCV) genotype 3 have a 12-week, once-daily, all-oral treatment option. Daklinza is indicated for use with sofosbuvir for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results